Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

1,867JPY
18 Aug 2017
Change (% chg)

¥-38 (-1.99%)
Prev Close
¥1,905
Open
¥1,884
Day's High
¥1,895
Day's Low
¥1,861
Volume
1,558,600
Avg. Vol
1,339,794
52-wk High
¥2,131
52-wk Low
¥1,412

4151.T

Chart for 4151.T

About

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of... (more)

Overall

Beta: 0.77
Market Cap(Mil.): ¥1,098,201.00
Shares Outstanding(Mil.): 576.48
Dividend: 12.50
Yield (%): 1.31

Financials

  4151.T Industry Sector
P/E (TTM): 48.37 31.59 32.70
EPS (TTM): 39.39 -- --
ROI: 3.49 15.32 14.88
ROE: 3.58 16.34 16.12

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

Aug 03 2017

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia

Apr 18 2017

BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its primary endpoint

* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint

Apr 06 2017

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

* Trial did not meet its primary endpoint of progression free survival (pfs).

Mar 27 2017

Earnings vs. Estimates